Surrozen (SRZN) Competitors $11.55 -0.04 (-0.35%) As of 02:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends SRZN vs. PRQR, EPRX, NBTX, SCPH, TSVT, ENTA, ACTU, CGEN, MGNX, and IKTShould you be buying Surrozen stock or one of its competitors? The main competitors of Surrozen include ProQR Therapeutics (PRQR), Eupraxia Pharmaceuticals (EPRX), Nanobiotix (NBTX), scPharmaceuticals (SCPH), 2seventy bio (TSVT), Enanta Pharmaceuticals (ENTA), Actuate Therapeutics (ACTU), Compugen (CGEN), MacroGenics (MGNX), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry. Surrozen vs. ProQR Therapeutics Eupraxia Pharmaceuticals Nanobiotix scPharmaceuticals 2seventy bio Enanta Pharmaceuticals Actuate Therapeutics Compugen MacroGenics Inhibikase Therapeutics Surrozen (NASDAQ:SRZN) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, community ranking, earnings, dividends and profitability. Which has more volatility and risk, SRZN or PRQR? Surrozen has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Does the MarketBeat Community favor SRZN or PRQR? ProQR Therapeutics received 331 more outperform votes than Surrozen when rated by MarketBeat users. Likewise, 61.99% of users gave ProQR Therapeutics an outperform vote while only 25.00% of users gave Surrozen an outperform vote. CompanyUnderperformOutperformSurrozenOutperform Votes525.00% Underperform Votes1575.00% ProQR TherapeuticsOutperform Votes33661.99% Underperform Votes20638.01% Which has preferable valuation and earnings, SRZN or PRQR? ProQR Therapeutics has higher revenue and earnings than Surrozen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSurrozen$10M3.75-$43.04MN/AN/AProQR Therapeutics$18.91M7.32-$30.43M-$0.34-4.99 Do insiders & institutionals believe in SRZN or PRQR? 66.6% of Surrozen shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 43.5% of Surrozen shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor SRZN or PRQR? In the previous week, ProQR Therapeutics had 14 more articles in the media than Surrozen. MarketBeat recorded 15 mentions for ProQR Therapeutics and 1 mentions for Surrozen. Surrozen's average media sentiment score of 1.87 beat ProQR Therapeutics' score of 0.50 indicating that Surrozen is being referred to more favorably in the media. Company Overall Sentiment Surrozen Very Positive ProQR Therapeutics Neutral Is SRZN or PRQR more profitable? Surrozen has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -134.31%. ProQR Therapeutics' return on equity of -71.58% beat Surrozen's return on equity.Company Net Margins Return on Equity Return on Assets SurrozenN/A -120.51% -54.68% ProQR Therapeutics -134.31%-71.58%-19.70% Do analysts rate SRZN or PRQR? Surrozen currently has a consensus price target of $38.50, suggesting a potential upside of 233.33%. ProQR Therapeutics has a consensus price target of $9.50, suggesting a potential upside of 460.47%. Given ProQR Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe ProQR Therapeutics is more favorable than Surrozen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Surrozen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 SummaryProQR Therapeutics beats Surrozen on 12 of the 17 factors compared between the two stocks. Remove Ads Get Surrozen News Delivered to You Automatically Sign up to receive the latest news and ratings for SRZN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRZN vs. The Competition Export to ExcelMetricSurrozenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.54M$3.11B$5.73B$8.16BDividend YieldN/A1.46%4.41%4.11%P/E RatioN/A28.3123.9419.22Price / Sales3.75438.21416.3289.30Price / CashN/A168.6838.0534.64Price / Book0.633.476.924.37Net Income-$43.04M-$71.72M$3.19B$246.99M7 Day Performance-1.03%2.32%9.97%4.10%1 Month Performance-1.37%-11.93%0.61%-7.87%1 Year Performance-9.70%-21.11%14.32%5.56% Surrozen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRZNSurrozen3.1352 of 5 stars$11.55-0.3%$38.50+233.3%-9.4%$37.54M$10M0.0080Positive NewsGap DownPRQRProQR Therapeutics2.4276 of 5 stars$1.81-5.2%$9.17+406.4%-34.0%$147.84M$17.88M-5.66180Analyst ForecastGap UpEPRXEupraxia Pharmaceuticals2.6772 of 5 stars$4.12-1.0%$10.50+154.9%N/A$146.86MN/A-5.7229NBTXNanobiotix1.9177 of 5 stars$3.09-7.8%$12.00+288.3%-53.7%$145.64M$36.22M0.00100Short Interest ↑SCPHscPharmaceuticals3.7844 of 5 stars$2.89-1.4%$15.00+419.0%-48.0%$144.62M$30.28M-1.5230Upcoming EarningsHigh Trading VolumeTSVT2seventy bio3.0775 of 5 stars$2.80+5.3%$7.20+157.1%+23.4%$144.45M$45.62M-1.51440Upcoming EarningsAnalyst ForecastENTAEnanta Pharmaceuticals4.3826 of 5 stars$6.77-6.2%$17.25+154.8%-53.2%$144.42M$66.59M-1.37160Short Interest ↓News CoverageACTUActuate TherapeuticsN/A$7.28+4.7%N/AN/A$142.19MN/A0.0010Analyst ForecastNews CoverageCGENCompugen1.8566 of 5 stars$1.59-4.2%$4.00+151.6%-39.6%$141.89M$27.86M79.5070Positive NewsMGNXMacroGenics4.0676 of 5 stars$2.23-1.8%$7.63+241.9%-86.1%$139.96M$139.77M-1.41430Upcoming EarningsIKTInhibikase Therapeutics0.9407 of 5 stars$1.99+1.5%$6.50+226.6%+6.6%$138.03M$260,000.00-0.756 Remove Ads Related Companies and Tools Related Companies PRQR Competitors EPRX Competitors NBTX Competitors SCPH Competitors TSVT Competitors ENTA Competitors ACTU Competitors CGEN Competitors MGNX Competitors IKT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRZN) was last updated on 3/17/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon Warns “America Is Broke”. Trump’s Plan Inside.Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surrozen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Surrozen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
